Latest News

The AHA and ASA have replaced their 2016 stroke rehabilitation guideline with expanded, evidence-graded recommendations helping clinicians decide on care settings, comorbidity management, and long-term recovery support.

A new case report underscored the need to consider CNS lymphoproliferative disease when patients on chronic immunosuppression for neuromyelitis optica spectrum disorder develop unexplained neurologic decline.

FDA approval of apitegromab introduces a muscle-targeting approach to SMA treatment, with phase 3 data demonstrating motor-function benefit when added to existing SMN2-directed therapies.

Sports neurologist Rory Siegel, DO, discusses the emerging evidence linking football participation with ALS, the potential role of repetitive head impacts, and key questions that remain about long-term neurological risk.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 11, 2026.

Mitzi Joi Williams, MD, is joined by Jakai McEwen, DO, and Charnetta Colton-Poole, MD, to discuss the challenges of communication between patients and their health care teams, including navigating medical language, promoting shared decision-making, and advocating for clear, patient-centered care.

The phase 3 LUNA study showed that atogepant, an oral calcitonin gene-related peptide receptor antagonist, significantly reduced perimenstrual migraine days among patients with menstrual migraine compared with placebo.

The AAN and AHS have replaced their 2012 migraine prevention guideline with new, evidence-graded recommendations, giving neurologists clearer direction on when to start preventive therapy, how to choose among older and newer options, and how to adjust treatment for specific patients.

The FDA granted priority review to satralizumab for MOGAD, positioning it to become the first approved treatment for the rare autoimmune disease.

Updated phase 1/2 POLARIS data showed sustained reductions in seizure frequency and progressive gains in cognitive and adaptive measures following a single administration of investigational ETX101 in children with SCN1A+ Dravet syndrome.

New real-world data showed that daily corticosteroid therapy preserved motor function longer in patients with Duchenne muscular dystrophy compared with an intermittent dosing regimen.

The clinical neuropsychologist and assistant professor of medicine at the Icahn School of Medicine at Mount Sinai discussed the mechanisms behind brain fog from Long COVID and its potential links to Alzheimer risk.

A new study suggests excessive daytime sleepiness in obstructive sleep apnea may be associated with cognitive impairment and altered brain network connectivity in the middle frontal gyrus and inferior parietal lobule.